SCHEMBL734692

SCHEMBL734692

CC(Nc1ccc(F)c(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.53
GRM4 Q14833 1/20 0.46
UBE2M P61081 3/20 0.43
DCUN1D1 Q96GG9 3/20 0.43
SLC22A12 Q96S37 1/20 0.43
HDAC8 Q9BY41 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
CES2 O00748 1/20 0.40
ABCB11 O95342 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735574 0.88 EPHX2 (0.46) ARSMN1; SMN2KDM4EKCNQ3KCNQ2
SCHEMBL1555605 0.88 SMN1; SMN2 (0.43) ARSMN1; SMN2KDM4ECES2ABCB11
SCHEMBL19951698 0.88 SMN1; SMN2 (0.43) ARSMN1; SMN2KDM4ECES2ABCB11
SCHEMBL734816 0.84 KDR (0.59) GRM4SMN1; SMN2LMNAHTT
SCHEMBL1555612 0.84 KDR (0.59) GRM4SMN1; SMN2LMNAHTT
SCHEMBL2336297 0.82 AR (0.54) ARGRM4UBE2MDCUN1D1SLC22A12
SCHEMBL13337046 0.82 AR (0.54) ARGRM4UBE2MDCUN1D1SLC22A12
SCHEMBL30047330 0.82 PTGS1 (0.48) ARSLC1A3SLC1A2SLC1A1SMN1; SMN2
SCHEMBL5661601 0.82 PTGS1 (0.48) ARSLC1A3SLC1A2SLC1A1SMN1; SMN2
SCHEMBL5661600 0.82 PTGS1 (0.48) ARSLC1A3SLC1A2SLC1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
CN-102112451-A Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2011-06-29 CN disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 AR 811/4885GRM4 438/4885UBE2M 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.